Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background

Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli

(2020) Wenhui Chen et al.   Annals of Translational Medicine

Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2

(2019) Peera Hemarajata et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime/avibactam carrying a novel KPC variant (KPC-36)

(2019) Paolo Gaibani et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment

(2018) Paolo Gaibani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

(2015) Romney M. Humphries et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY